AUTHORS
Xi Zhang, MD, Shiyi Yuan, MD2, Ying Zhou, MD3, Yan Shen, MD4, Jianchuan Deng, MD5, Shifeng Lou, MD6, wenrui Xiao7
AFFILIATIONS
1 Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, Chongqing, China, Chongqing, China
2 The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
4 The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
5 The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
6 The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
7 The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
ABSTRACT
background:
Chemotherapy resistance represents a critical therapeutic barrier in T-cell acute lymphoblastic leukemia (T-ALL). Liver regeneration enhancer (ALR) is aberrantly upregulated in T-ALL and drives chemoresistance via suppressing mitochondrial apoptosis. However, whether ALR modulates other cell death modalities, especially ferroptosis, and its underlying regulatory mechanism in T-ALL chemoresistance remain undefined.
Methods
Human T-ALL cell lines (Jurkat and Molt-4) with stable ALR knockdown were constructed for in vitro functional verification. Intracellular reactive oxygen species, ferrous ion levels, lipid peroxidation, and arachidonic acid (AA) content were detected to evaluate ferroptosis activation. Cell morphological changes were observed via mitochondrial ultrastructure analysis. Rescue experiments using ferroptosis inhibitor Ferrostatin-1 (Fer-1) and apoptosis inhibitors were performed to clarify the dominant cell death pathway. Transcriptomic profiling and biochemical assays were applied to identify the downstream signaling axis. Relapsed/refractory (R/R) T-ALL primary patient cells (n=5) and mouse xenograft models were utilized for clinical relevance and in vivo validation, with FADS2 inhibitor SC-26196 used for mechanism rescue verification.
Results
ALR knockdown significantly triggered ferroptotic phenotypes in T-ALL cells, including elevated reactive oxygen species, ferrous ions, lipid peroxidation, and AA accumulation, as well as mitochondrial ruffling and cristae loss. Fer-1 completely reversed ALR depletion-induced cell death, whereas apoptosis inhibitors only exerted partial rescue effects, confirming ferroptosis as the predominant cell death pathway upon ALR loss. Mechanistically, ALR negatively modulates the AMPK/SREBP1/FADS2 signaling axis. ALR knockdown reduced AMPK Thr172 phosphorylation, further decreased inhibitory SREBP1 Ser372 phosphorylation, facilitated nuclear translocation of mature SREBP1, and upregulated FADS2 expression — the rate-limiting enzyme for polyunsaturated fatty acid (PUFA) synthesis. Increased membrane PUFA accumulation in ALR-deficient T-ALL cells enhanced ferroptosis susceptibility. ALR depletion sensitized T-ALL cells to dexamethasone (DEX) plus methotrexate (MTX) chemotherapy in a Fer-1-reversible manner, indicating ALR-mediated chemoresistance is partially dependent on ferroptosis inhibition. In primary R/R T-ALL cells, supplementation with AA or docosahexaenoic acid (DHA) elevated the PUFA/MUFA ratio and lipid peroxidation, remodeled GPX4/ACSL4 expression, and restored chemosensitivity, and all these phenotypic changes were abrogated by Fer-1. In vivo, ALR knockdown alone alleviated leukemia burden and prolonged mouse survival, and combined ALR knockdown with DEX+MTX achieved synergistic anti-leukemic effects, which were partially blocked by FADS2 inhibition.
Conclusions
This study identifies a novel ALR-regulated AMPK/SREBP1/FADS2 signaling axis that mediates T-ALL chemoresistance via ferroptosis suppression. Targeting this axis through ALR silencing, AMPK/SREBP1 inhibition, or exogenous PUFA supplementation restores ferroptosis sensitivity and reverses chemotherapy resistance. Metabolic intervention strategies, especially dietary PUFA supplementation, possess promising therapeutic value for the treatment of R/R T-ALL.
DISCLOSURES
Ying Zhou, MD: No relevant conflicts of interest to declare.